Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Sorafenib for relapsed FLT3-ITD-positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis.

Brodie R, Langabeer SE, Quinn J, McMenamin ME, Hayden PJ.

Clin Case Rep. 2019 Oct 19;7(12):2579-2580. doi: 10.1002/ccr3.2487. eCollection 2019 Dec.

2.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

3.

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.

Hayden PJ, Iacobelli S, Pérez-Simón JA, van Biezen A, Minnema M, Niittyvuopio R, Schönland S, Meijer E, Blaise D, Milpied N, Márquez-Malaver FJ, Veelken JH, Maertens J, Michallet M, Cammenga J, N'Guyen S, Niederwieser D, Hunault-Berger M, Bourhis JH, Passweg J, Bermudez A, Chalandon Y, Yakoub-Agha I, Garderet L, Kröger N.

Eur J Haematol. 2020 Mar;104(3):181-189. doi: 10.1111/ejh.13352. Epub 2019 Dec 25.

PMID:
31737951
4.

An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.

Hayden PJ, Sirait T, Koster L, Snowden JA, Yakoub-Agha I.

Curr Res Transl Med. 2019 Aug;67(3):79-88. doi: 10.1016/j.retram.2019.05.002. Epub 2019 Jun 8.

PMID:
31182380
5.

Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.

Broderick V, Waghorn K, Langabeer SE, Jeffers M, Cross NCP, Hayden PJ.

Leuk Res. 2019 Feb;77:28-29. doi: 10.1016/j.leukres.2018.12.010. Epub 2018 Dec 24. No abstract available.

PMID:
30612056
6.

Prevalidation of an Acute Inhalation Toxicity Test Using the EpiAirway In Vitro Human Airway Model.

Jackson GR Jr, Maione AG, Klausner M, Hayden PJ.

Appl In Vitro Toxicol. 2018 Jun 1;4(2):149-158. doi: 10.1089/aivt.2018.0004.

7.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS.

Ann Hematol. 2018 May;97(5):839-849. doi: 10.1007/s00277-018-3237-5. Epub 2018 Jan 23.

PMID:
29359239
8.

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

Lehners N, Hayden PJ, Goldschmidt H, Raab MS.

Expert Rev Hematol. 2016 Aug;9(8):753-65. doi: 10.1080/17474086.2016.1204908. Epub 2016 Jul 4. Review.

PMID:
27337562
9.

Bortezomib for the treatment of multiple myeloma.

Scott K, Hayden PJ, Will A, Wheatley K, Coyne I.

Cochrane Database Syst Rev. 2016 Apr 20;4:CD010816. doi: 10.1002/14651858.CD010816.pub2. Review.

PMID:
27096326
10.

Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.

Lavin M, Brophy TM, Rawley O, O'Sullivan JM, Hayden PJ, Browne PV, Ryan K, O'Connell N, O'Donnell JS.

J Thromb Haemost. 2016 Jun;14(6):1200-5. doi: 10.1111/jth.13317. Epub 2016 Apr 27.

11.

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.

Langabeer SE, Haslam K, O'Brien D, Kelly J, Andrews C, Ryan C, Flavin R, Hayden PJ, Bacon CL.

Case Rep Hematol. 2016;2016:6545861. doi: 10.1155/2016/6545861. Epub 2016 Jan 21.

12.

A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.

O'Kane G, Bracken-Clarke D, Gardiner N, Lee G, Ni Chonghaile M, Power D, Daly PA, McCaffrey J, Bacon CL, Conneally E, Flynn C, Vandenberghe E, Kennedy MJ, Browne PV, O'Donnell DM, Hayden PJ.

Bone Marrow Transplant. 2016 Jun;51(6):856-9. doi: 10.1038/bmt.2015.354. Epub 2016 Feb 8. No abstract available.

PMID:
26855151
13.

Comprehensive evaluation of poly(I:C) induced inflammatory response in an airway epithelial model.

Lever AR, Park H, Mulhern TJ, Jackson GR, Comolli JC, Borenstein JT, Hayden PJ, Prantil-Baun R.

Physiol Rep. 2015 Apr;3(4). pii: e12334. doi: 10.14814/phy2.12334.

14.

Phenotypic responses of differentiated asthmatic human airway epithelial cultures to rhinovirus.

Bai J, Smock SL, Jackson GR Jr, MacIsaac KD, Huang Y, Mankus C, Oldach J, Roberts B, Ma YL, Klappenbach JA, Crackower MA, Alves SE, Hayden PJ.

PLoS One. 2015 Feb 23;10(2):e0118286. doi: 10.1371/journal.pone.0118286. eCollection 2015.

15.

DNA photoprotection conveyed by sunscreen.

DeHaven C, Hayden PJ, Armento A, Oldach J.

J Cosmet Dermatol. 2014 Jun;13(2):99-102. doi: 10.1111/jocd.12087.

PMID:
24910272
16.

Symptomatic BK virus reactivation following fludarabine, cyclophosphamide and rituximab chemotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma.

Appleby N, Dillon A, Arrigan M, Fennell J, Crowley B, Hayden PJ, Enright H.

Leuk Lymphoma. 2014 May;55(5):1181-3. doi: 10.3109/10428194.2013.838763. Epub 2013 Oct 9. No abstract available.

PMID:
23987823
17.

An immunophenotypic and molecular diagnosis of composite hairy cell leukaemia and chronic lymphocytic leukaemia.

Liptrot S, O' Brien D, Langabeer SE, Quinn F, Mackarel AJ, Elder P, Vandenberghe E, Hayden PJ.

Med Oncol. 2013 Dec;30(4):692. doi: 10.1007/s12032-013-0692-7. Epub 2013 Aug 24.

PMID:
23979856
18.

CaMKII is essential for the proasthmatic effects of oxidation.

Sanders PN, Koval OM, Jaffer OA, Prasad AM, Businga TR, Scott JA, Hayden PJ, Luczak ED, Dickey DD, Allamargot C, Olivier AK, Meyerholz DK, Robison AJ, Winder DG, Blackwell TS, Dworski R, Sammut D, Wagner BA, Buettner GR, Pope RM, Miller FJ Jr, Dibbern ME, Haitchi HM, Mohler PJ, Howarth PH, Zabner J, Kline JN, Grumbach IM, Anderson ME.

Sci Transl Med. 2013 Jul 24;5(195):195ra97. doi: 10.1126/scitranslmed.3006135.

19.

Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods.

Leist M, Lidbury BA, Yang C, Hayden PJ, Kelm JM, Ringeissen S, Detroyer A, Meunier JR, Rathman JF, Jackson GR Jr, Stolper G, Hasiwa N.

ALTEX. 2012;29(4):373-88. doi: 10.14573/altex.2012.4.373.

PMID:
23138508
20.

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A.

Cancer Res. 2012 Oct 15;72(20):5374-85. doi: 10.1158/0008-5472.CAN-12-2026. Epub 2012 Aug 31.

21.

Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype.

Langabeer SE, O'Brien D, Liptrot S, Flynn CM, Hayden PJ, Conneally E, Browne PV, Vandenberghe E.

Int J Lab Hematol. 2012 Aug;34(4):417-21. doi: 10.1111/j.1751-553X.2012.01402.x. Epub 2012 Feb 7.

PMID:
22313586
22.

Genetic variation at the 8q24 locus confers risk to multiple myeloma.

Tewari P, Ryan AW, Hayden PJ, Catherwood M, Drain S, Staines A, Grant T, Nieters A, Becker N, de Sanjose S, Foretova L, Maynardie M, Cocco P, Boffetta P, Brennan P, Chanock S, Lawler M, Browne PV.

Br J Haematol. 2012 Jan;156(1):133-6. doi: 10.1111/j.1365-2141.2011.08798.x. Epub 2011 Jul 19. No abstract available.

PMID:
21770920
23.

Regulation of Hsp27 and Hsp70 expression in human and mouse skin construct models by caveolae following exposure to the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide.

Black AT, Hayden PJ, Casillas RP, Heck DE, Gerecke DR, Sinko PJ, Laskin DL, Laskin JD.

Toxicol Appl Pharmacol. 2011 Jun 1;253(2):112-20. doi: 10.1016/j.taap.2011.03.015. Epub 2011 Mar 30.

24.

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J.

Bone Marrow Transplant. 2012 Jan;47(1):18-23. doi: 10.1038/bmt.2011.9. Epub 2011 Feb 28.

PMID:
21358693
25.

A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.

McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, Hayden PJ, Langabeer SE.

Leuk Lymphoma. 2011 May;52(5):919-21. doi: 10.3109/10428194.2011.555025. Epub 2011 Feb 21. No abstract available.

PMID:
21338279
26.

Expression of proliferative and inflammatory markers in a full-thickness human skin equivalent following exposure to the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide.

Black AT, Hayden PJ, Casillas RP, Heck DE, Gerecke DR, Sinko PJ, Laskin DL, Laskin JD.

Toxicol Appl Pharmacol. 2010 Dec 1;249(2):178-87. doi: 10.1016/j.taap.2010.09.005. Epub 2010 Sep 16.

27.

Xenobiotic metabolism gene expression in the EpiDermin vitro 3D human epidermis model compared to human skin.

Hu T, Khambatta ZS, Hayden PJ, Bolmarcich J, Binder RL, Robinson MK, Carr GJ, Tiesman JP, Jarrold BB, Osborne R, Reichling TD, Nemeth ST, Aardema MJ.

Toxicol In Vitro. 2010 Aug;24(5):1450-63. doi: 10.1016/j.tiv.2010.03.013. Epub 2010 Mar 27.

PMID:
20350595
28.

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.

Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24.

29.

Dynamic and physical clustering of gene expression during epidermal barrier formation in differentiating keratinocytes.

Taylor JM, Street TL, Hao L, Copley R, Taylor MS, Hayden PJ, Stolper G, Mott R, Hein J, Moffatt MF, Cookson WO.

PLoS One. 2009 Oct 30;4(10):e7651. doi: 10.1371/journal.pone.0007651.

30.

Microvesicating effects of sulfur mustard on an in vitro human skin model.

Hayden PJ, Petrali JP, Stolper G, Hamilton TA, Jackson GR Jr, Wertz PW, Ito S, Smith WJ, Klausner M.

Toxicol In Vitro. 2009 Oct;23(7):1396-405. doi: 10.1016/j.tiv.2009.07.021. Epub 2009 Jul 18.

PMID:
19619636
31.

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, Fruehauf JH, Lin BK, Chauhan D, Hideshima T, Munshi NC, Anderson KC, Podar K.

Blood. 2009 Feb 12;113(7):1513-21. doi: 10.1182/blood-2008-05-157040. Epub 2008 Nov 18.

32.

From the bench to the bedside: emerging new treatments in multiple myeloma.

Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG.

Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816. Review.

33.

Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma.

Hayden PJ, Tewari P, Morris DW, Staines A, Crowley D, Nieters A, Becker N, de Sanjosé S, Foretova L, Maynadié M, Cocco PL, Boffetta P, Brennan P, Chanock SJ, Browne PV, Lawler M.

Hum Mol Genet. 2007 Dec 15;16(24):3117-27. Epub 2007 Sep 26.

PMID:
17901044
34.

Novel therapies in myeloma.

Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.

Curr Opin Hematol. 2007 Nov;14(6):609-15. Review.

PMID:
17898564
35.

Concurrent rearrangement of BCL1 and BCL6 with a single immunoglobulin locus in a case of diffuse large B-cell lymphoma.

Ní Ainle F, Hayden PJ, Crosby P, Murphy K, McCarthy D, Kelly J, Neat MJ.

Leuk Lymphoma. 2006 Dec;47(12):2655-6. No abstract available.

PMID:
17169813
36.

Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo.

Agu RU, Valiveti S, Paudel KS, Klausner M, Hayden PJ, Stinchcomb AL.

J Pharm Pharmacol. 2006 Nov;58(11):1459-65.

PMID:
17132208
37.

The value of autofluorescence as a diagnostic feature of acute promyelocytic leukemia.

Hayden PJ, O'Connell NM, O'Brien DA, O'Rourke P, Lawlor E, Browne PV.

Haematologica. 2006 Mar;91(3):417-8.

38.
39.

Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003.

Hayden PJ, O'Driscoll A, Gardiner N, Swords R, Sargent J, Ni Ainle F, Fortune A, Murphy PT, Leahy M, Jackson F, Ryan M, Hennessy B, Cahill M, Crotty GM, Enright H, Conneally E, Vandenberghe E, McCann SR, Browne PV.

Ir J Med Sci. 2005 Apr-Jun;174(2):26-32.

PMID:
16094909
40.

Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST.

Hayden PJ, Crampe M, Lawler M, Conneally E, McCann SR, Vandenberghe E, Browne PV.

Bone Marrow Transplant. 2005 Oct;36(8):735-6. No abstract available.

PMID:
16044131
41.

Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats.

Agu RU, Valiveti S, Earles DC, Klausner M, Hayden PJ, Wermeling DP, Stinchcomb AL.

Endocr Res. 2004 Aug;30(3):455-67.

PMID:
15554361
42.

Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.

Swords R, Hayden PJ, Molloy K, Lawlor M, Browne PV, Murphy PT.

Eur J Haematol. 2004 Dec;73(6):450-1. No abstract available.

PMID:
15522070
43.

A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase.

Hayden PJ, Keogh F, Ni Conghaile M, Carroll M, Crowley M, Fitzsimon N, Gardiner N, Vandenberghe E, O'Riordan J, McCann SR.

Bone Marrow Transplant. 2004 Sep;34(6):545-56.

PMID:
15343272
44.

Full Thickness EpiDerm: a dermal-epidermal skin model to study epithelial-mesenchymal interactions.

Kubilus J, Hayden PJ, Ayehunie S, Lamore SD, Servattalab C, Bellavance KL, Sheasgreen JE, Klausner M.

Altern Lab Anim. 2004 Jun;32 Suppl 1A:75-82.

PMID:
23577437
45.

Pure red cell aplasia after a major ABO-mismatched bone marrow transplant for chronic myeloid leukaemia: response to re-introduction of cyclosporin.

Hayden PJ, Gardiner N, Molloy K, Ryan J, Lawler M, McCann SR.

Bone Marrow Transplant. 2004 Feb;33(4):459-61. No abstract available.

PMID:
14676777
46.

Inherited thrombotic tendency in a pedigree with antithrombin La Rochelle (N405K) and factor V Leiden.

Hayden PJ, O'Brien M, Collins B, O'Farrelly C, Murphy K.

Clin Lab Haematol. 2003 Jun;25(3):191-3.

PMID:
12755798
47.

Anthralin stimulates keratinocyte-derived proinflammatory cytokines via generation of reactive oxygen species.

Lange RW, Hayden PJ, Chignell CF, Luster MI.

Inflamm Res. 1998 Apr;47(4):174-81.

PMID:
9628260
48.

An EPR study of free radicals formed by antipsoriatic and tumor-promoting 9-anthrones in nonpolar solvents.

Motten AG, Sik RH, Chignell CF, Hayden PJ.

Chem Res Toxicol. 1994 Nov-Dec;7(6):877-81.

PMID:
7696546
49.
50.

Differential cellular effects in the toxicity of haloalkene and haloalkane cysteine conjugates to rabbit renal proximal tubules.

Groves CE, Hayden PJ, Lock EA, Schnellmann RG.

J Biochem Toxicol. 1993 Mar;8(1):49-56.

PMID:
8492303

Supplemental Content

Loading ...
Support Center